{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?uin=126328&max-answer.questionFirstAnswered.=2019-06-18T16%3A37%3A00.307Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?uin=126328&max-answer.questionFirstAnswered.=2019-06-18T16%3A37%3A00.307Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?uin=126328&_metadata=all&max-answer.questionFirstAnswered.=2019-06-18T16%3A37%3A00.307Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&uin=126328&max-answer.questionFirstAnswered.=2019-06-18T16%3A37%3A00.307Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?uin=126328&max-answer.questionFirstAnswered.=2019-06-18T16%3A37%3A00.307Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?uin=126328&max-answer.questionFirstAnswered.=2019-06-18T16%3A37%3A00.307Z", "items" : [{"_about" : "http://data.parliament.uk/resources/835973", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/835973/answer", "answerText" : {"_value" : "<p>No assessment has been made. However, the Government is working in collaboration with the sector to realise the vision of the strategy to ensure the United Kingdom remains a top-tier global hub for clinical research and medical innovation, and ensure that the benefits of these innovations will be felt by UK patients. For example, the Government is investing up to £210 million in an early diagnostics challenge that will help patients benefit from earlier, more accurate diagnosis and more effective treatments. We have also published the response to the Accelerated Access Review which includes the introduction of a new Accelerated Access Pathway and £86 million of funding to support medical innovations get to patients faster.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2018-02-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-02-09T12:08:07.24Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-02-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Chronic Illnesses: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential effect of the proposals in the Life Sciences Strategy on treatments for people with (a) cystic fibrosis and (b) other long-term conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
      }
      , "tablingMemberConstituency" : {"_value" : "York Outer"}
      , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
      ], "uin" : "126328"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}